Sunitinib in Treating Patients With Kidney Cancer That Cannot Be Removed by Surgery
Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Sunitinib may stop the growth of kidney cancer by blocking blood flow to the tumor
and by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying the side effects and how well sunitinib works in
treating patients with kidney cancer that cannot be removed by surgery.